News center

1、 Technological innovation: a leap from "innovation" to "painlessness"

Intelligent puncture robot overturns traditional operations

The FUXI intelligent infusion robot developed by Fuxi Jiuzhen overcomes the problem of automatic positioning of the hand vein puncture target through multimodal fusion technology (infrared blood vessel recognition+ultrasound guidance+force sensing follow-up system), achieving a 1-minute completion of puncture. Its equipment supports multi site (back of hand, elbow, leg) puncture and is compatible with dual functions of blood collection and infusion. It has been tested in 200 tertiary hospitals.

Mini catheter technology reduces vascular damage

The ultra-fine mini catheter (diameter 0.5mm) launched by Tongchuan Mining Bureau Central Hospital, combined with ultrasound-guided puncture, can be retained for 7-15 days and is suitable for patients undergoing tumor chemotherapy and long-term antibiotic treatment. The puncture failure rate is reduced by 40% compared to traditional steel needles. This technology reduces the risk of drug extravasation through deep vein placement and increases patient mobility by 80%.

Breakthrough in needle free transdermal infusion technology

The patch type infusion patch developed by the Zhejiang University team uses a coin sized microneedle device to achieve 24-hour continuous administration, suitable for chemotherapy drugs (such as cytarabine) and hypoglycemic drugs (such as exenatide), with a dose of up to 225mg/day, which is three times more efficient than traditional subcutaneous injection.

2、 Clinical Application: Balancing Precision Medicine and Comfortable Experience

Standardization of vascular assessment

Based on the standards of the American Society of Intravenous Nursing (INS), a four-dimensional grading system (diameter, elasticity, exposure, fixability) has been introduced in clinical practice, combined with ultrasound-guided technology, to increase the success rate of puncture in obese and poorly vascularized patients from 62% to 89%.

Vascular protection strategies for cancer patients

Priority should be given to selecting expensive veins (blood flow ≥ 40ml/min), using 10 ° -15 ° micro angle puncture technology, combined with physiological saline pre flushing tubing, to reduce the incidence of phlebitis from 18% to 5%.

Innovation of Pediatric Puncture Technology

Develop 3 ° -5 ° minimally invasive puncture needles for newborns and premature infants, combined with portable vascular imaging devices and temperature protection pads, to reduce the puncture penetration rate from 22% to 8% and extend the retention time to 72 hours.

3、 Industry Trend: Policy and Demand Driven Upgrade

The 'limited resistance order' accelerates the optimization of product structure

Henan Province has completely abolished outpatient infusion fees, promoted medical institutions to reduce non essential intravenous infusion, and forced enterprises to focus on high value-added products (such as targeted infusion systems and sustained-release multi chamber bags). Among them, Shiyao Group's "Liposomal Doxorubicin Injection" has a tumor targeting efficiency of 90%.

Centralized procurement reshapes the market landscape

The EU has launched an anti-dumping investigation into Chinese infusion packaging materials, with tariffs increasing by 15% -20%, prompting leading companies such as Kelun Pharmaceutical and Huaren Pharmaceutical to accelerate their overseas production capacity layout and increase concentration through mergers and acquisitions (such as Kelun's acquisition of 20% equity in Shisi Pharmaceutical).

Environmental Protection and Intelligent Transformation

Shandong Weigao Group launches PLA biodegradable infusion bags, reducing carbon emissions by 70%; The Lianying intelligent infusion robot achieves unmanned operation throughout the entire process, reducing single hospital procurement costs by 30%.

4、 Challenges and Prospects

Cost pressure: The price of medical grade stainless steel needle tubes has increased by 12%, coupled with the extension of the FDA 510k audit cycle to 18 months, and the expected elimination rate for small and medium-sized enterprises is 25%.

Emerging market opportunities: The demand for medical infrastructure in Africa and Southeast Asia has surged, and Tiankang Medical's Rwanda factory produces 300 million safety syringes annually, filling the local supply chain gap.